---
title: "Q-Linea wins Premier contract position for ASTar rapid susceptibility testing system in US"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296207937.md"
description: "Q-Linea secured a contract with Premier, granting over 4,000 member hospitals access to pre-negotiated pricing for its ASTar rapid susceptibility testing system. Effective September 1, 2026, the agreement covers the ASTar instrument and BC G- kit. This deal aims to streamline U.S. procurement processes, shorten sales cycles, and accelerate adoption among Premier's network of institutions."
datetime: "2026-08-18T09:47:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296207937.md)
  - [en](https://longbridge.com/en/news/296207937.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296207937.md)
generator: "portal-rs"
---

# Q-Linea wins Premier contract position for ASTar rapid susceptibility testing system in US

-   Q-linea won a contract position with Premier, giving more than 4,000 member hospitals access to pre-negotiated ASTar pricing. \* Agreement takes effect Sept. 1, 2026, covering the ASTar instrument and the ASTar BC G- kit. \* Deal is expected to shorten U.S. sales cycles by simplifying procurement, supporting faster adoption across Premier member institutions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q-Linea AB published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PINC.US](https://longbridge.com/en/quote/PINC.US.md)

## Related News & Research

- [BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier | BSEM Stock News](https://longbridge.com/en/news/298031320.md)
- [Pharvaris rises on late-stage trial win for hereditary angioedema drug](https://longbridge.com/en/news/298315480.md)
- [Intelligent Bio Solutions submits FDA 510(k) filing for fingerprint drug test system seeking codeine clearance](https://longbridge.com/en/news/298458663.md)
- [Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition](https://longbridge.com/en/news/298349678.md)
- [CHEMM: Strong instrument sales and margin expansion drive growth, with robust outlook for automation](https://longbridge.com/en/news/298742893.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**